Health
FDA approves Imaavy, first cleared treatment for warm autoimmune hemolytic anemia
- Johnson & Johnson’s Imaavy is cleared for patients aged 12 and older with warm autoimmune hemolytic anemia.
Written by AI1 source1 min
Loading…
Diagnostics, prosthetics, vaccines, genomics: the medicine that adds years to a life.
Medicine that wins years of life: AI-assisted screening examining millions of patients, next-generation vaccines, genomics moving from sequencing to treatment, prosthetics and implants restoring lost abilities. The section follows completed clinical trials, market authorisations, hospital roll-outs — the moment a technology stops being a paper and becomes care.
The numbers rule: cohorts, detection rates, avoided mortality, costs. We gladly cover the health systems deploying at scale — India, Brazil, Southeast Asia — because frugal technologies often prove themselves there before arriving anywhere else. Every article rests on the trial, authorisation or study behind it, and cites them.
- Johnson & Johnson’s Imaavy is cleared for patients aged 12 and older with warm autoimmune hemolytic anemia.
The TEAMSS initiative worked with 160 clinicians at 27 pediatric clinics across 18 states.
The circuit links the amygdala and prefrontal cortex, two regions involved in emotion and decision-making.
Northwestern researchers tested more than 1,900 NAT10 variants in one proliferation assay.
L-32 targets PTPN22, a protein that restrains immune activity.
The system estimates both tumor volume and where its segmentation may be wrong.
Penn State researchers tested 12 guinea fowl, six of which carried weights equal to 4% of body weight during growth.
At one year, 23.6% of thrombectomy patients were functionally independent, versus 6.8% receiving medical care.
The cells carry CHL1, a gene not normally found on healthy-lung fibroblasts.
The combination pushed tumor-cell DNA damage beyond repair, triggering programmed cell death.
Researchers at National Taiwan University built the first spatial map of ovarian clear cell carcinoma.
The changes differ between infectious and noninfectious forms of Trypanosoma cruzi.
The STAR-TREC phase 2/3 trial enrolled more than 500 patients across five European countries.
- The regimen alternated 24 hours of fasting with 24 hours of unrestricted feeding for 38 days.
Peter Mac researchers identified four proteins pancreatic cancer cells rely on to grow and survive.
Georgia State's method aligns brain timescales before comparing network signal strength.
A Cornell team activated macrophages after targeted therapy to recruit immune cells against resistant melanoma cells.
The recordings came from 23 patients during deep brain stimulation surgery.